Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole Concentrations in BALF and CSF in Adult Invasive Fungal Disease
ChiCTR2600122663Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of isavuconazole in invasive aspergillosis (IA) and mucormycosis, sponsored by Huashan Hospital. Primary endpoint: Minimum concentrations in serum, bronchoalveolar lavage fluid, and cerebrospinal fluid. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on ChiCTR2600122663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122663.